WASHINGTON D.C (VINnews) — President Trump said Monday that he has reached new voluntary pricing agreements with nine pharmaceutical companies, expanding an administration effort to bring U.S. prescription drug prices closer to those charged in other wealthy countries.
Join our WhatsApp groupSubscribe to our Daily Roundup Email
The companies are Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi, according to White House and industry reports. The deals build on earlier most-favored-nation arrangements with other major manufacturers and are tied to the administration’s TrumpRx direct-to-consumer platform.
Under the most-favored-nation approach, participating companies agree to offer certain medicines at prices comparable to the lowest they charge in other developed nations. Officials say the latest agreements cover drugs sold to Medicaid and some cash-paying patients, and that future product launches from the companies will also be offered at those benchmark prices.
Trump has argued that Americans have long subsidized lower prices abroad. The administration has used the threat of tariffs and other pressure to secure the voluntary deals. Participating companies have received multiyear tariff relief in return.
Bristol Myers Squibb separately said it will provide its blood thinner Eliquis at no cost to Medicaid beneficiaries. Other examples cited in earlier White House fact sheets for this group of companies include steep list-price discounts on selected products such as Amgen’s cholesterol drug Repatha, GSK inhalers and Merck diabetes medicines when sold through TrumpRx.
The White House has said 17 of the largest drugmakers, representing the bulk of the branded market, have now signed similar agreements. TrumpRx launched earlier in 2026 and lists discounted cash prices on dozens of brand-name drugs.
Critics and some analysts have noted that many of the featured products already face generic or biosimilar competition, that Medicaid already receives large statutory rebates, and that list-price cuts on a limited set of drugs do not automatically lower what insured patients or Medicare pay. Independent verification of overall savings has been limited because full contract details have not been made public.
Trump described the latest agreements as part of a broader effort to end what he called “global freeloading” on American pharmaceutical innovation. Additional companies were expected to announce similar terms, officials said.